Abstract 5106
Background
Obesity is a well-known risk factor for colorectal cancer (CRC), the relative risk being higher in men than in women, and for colon than for rectal cancer. Whether this risk differs by sidedness of colon cancer and sex, has however not yet been explored.
Methods
Among 28098 participants in the Malmö Diet and Cancer study, 11063 men and 17035 women, 584 incident CRC cases had been registered by Dec 31 2008. Seven anthropometric factors; height, weight, bodyfat%, hip circumference, waist circumference, BMI and waist-hip ratio (WHR) were categorized into quartiles (Q). Hazard ratios (HR) of CRC risk according to tumour location (right colon, left colon, rectum) and sex were calculated using multivariable Cox regression models, adjusted for age, smoking, educational level and alcohol intake.
Results
In men, several anthropometric factors were associated with an increased risk of right-sided colon cancer (HR for Q1[ref]-Q4 for weight 1.0, 1.67, 1.99, 2.88, ptrend= 0.001; waist circumference 1.0, 0.64, 1.59, 2.03, ptrend= 0.002; WHR 1.0, 0.73, 1.93, 1.89, ptrend= 0.004; BMI 1.0, 1.29, 1.50, 2.64, ptrend= 0.001), only WHR with left-sided colon cancer (1.0, 1.26, 1.94, 2.06, ptrend= 0.021), and none with rectal cancer. In women, body size was not associated with risk for neither right-sided nor left-sided colon cancer, only with rectal cancer (bodyfat% 1.0, 1.57, 2.18, 1.94, ptrend= 0.032, hip circumference 1.0, 1.76, 1.45, 2.18, ptrend= 0.033). Significant interactions with sex were denoted for hip circumference (p = 0.032) and BMI (p = 0.026) in relation to risk of right-sided colon cancer.
Conclusions
These data unveil a sexual dimorphism in the relationship between obesity and right-sided colon cancer, only being evident in men. As right-sided tumours are otherwise more common in women, hormonal factors may be particularly influential in their carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lund University.
Funding
The Swedish Cancer Society, the Swedish Research Council, the Swedish Government Grant for Clinical Research, the Mrs Berta Kamprad Foundation, Lund University Faculty of Medicine and University Hospital Research Grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract
4401 - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
Presenter: Jonathan Kish
Session: Poster Display session 2
Resources:
Abstract
5876 - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter ‘Real-World’ Patients (pts) Series.
Presenter: Armando Orlandi
Session: Poster Display session 2
Resources:
Abstract
3587 - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
Presenter: E Dees
Session: Poster Display session 2
Resources:
Abstract
5696 - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)
Presenter: Sacha Howell
Session: Poster Display session 2
Resources:
Abstract
1475 - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
2549 - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3787 - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
Presenter: Binghe Xu
Session: Poster Display session 2
Resources:
Abstract
4835 - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Presenter: Huiping Li
Session: Poster Display session 2
Resources:
Abstract
5083 - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Presenter: Jin-Hee Ahn
Session: Poster Display session 2
Resources:
Abstract